To develop and validate interpretable machine learning models for differentiating glioblastoma (GB) from solitary brain metastasis (SBM) using radiomics features from contrast-enhanced T1-weighted MRI (CE-T1WI), and to compare the impact of low-order and high-order features on model performance. A cohort of 434 patients with histopathologically confirmed GB (226 patients) and SBM (208 patients) was retrospectively analyzed. Radiomic features were derived from CE-T1WI, with feature selection conducted through minimum redundancy maximum relevance and least absolute shrinkage and selection operator regression. Machine learning models, including GradientBoost and lightGBM (LGBM), were trained using low-order and high-order features. The performance of the models was assessed through receiver operating characteristic analysis and computation of the area under the curve, along with other indicators, including accuracy, specificity, and sensitivity. SHapley Additive Explanations (SHAP) analysis is used to measure the influence of each feature on the model's predictions. The performances of various machine learning models on both the training and validation datasets were notably different. For the training group, the LGBM, CatBoost, multilayer perceptron (MLP), and GradientBoost models achieved the highest AUC scores, all exceeding 0.9, demonstrating strong discriminative power. The LGBM model exhibited the best stability, with a minimal AUC difference of only 0.005 between the training and test sets, suggesting strong generalizability. Among the validation group results, the GradientBoost classifier achieved the maximum AUC of 0.927, closely followed by random forest at 0.925. GradientBoost also demonstrated high sensitivity (0.911) and negative predictive value (NPV, 0.889), effectively identifying true positives. The LGBM model showed the highest test accuracy (86.2%) and performed excellently in terms of sensitivity (0.911), NPV (0.895), and positive predictive value (PPV, 0.837). The models utilizing high-order features outperformed those based on low-order features in all the metrics. SHAP analysis further enhances model interpretability, providing insights into feature importance and contributions to classification decisions. Machine learning techniques based on radiomics can effectively distinguish GB from SBM, with gradient boosting tree-based models such as LGBMs demonstrating superior performance. High-order features significantly improve model accuracy and robustness. SHAP technology enhances the interpretability and transparency of models for distinguishing brain tumors, providing intuitive visualization of the contribution of radiomic features to classification.

Early detection of malignant lesions in ultrasound images is crucial for effective cancer diagnosis and treatment. While traditional methods rely on radiologists, deep learning models can improve accuracy, reduce errors, and enhance efficiency. This study explores the application of a deep learning model for classifying benign and malignant lesions, focusing on its performance and interpretability. In this study, we proposed a feature fusion-based deep learning model for classifying benign and malignant lesions in ultrasound images. The model leverages advanced architectures such as MobileNetV2 and DenseNet121, enhanced with feature fusion and attention mechanisms to boost classification accuracy. The clinical dataset comprises 2171 images collected from 1758 patients between December 2020 and May 2024. Additionally, we utilized the publicly available BUSI dataset, consisting of 780 images from female patients aged 25 to 75, collected in 2018. To enhance interpretability, we applied Grad-CAM, Saliency Maps, and shapley additive explanations (SHAP) techniques to explain the model's decision-making. A comparative analysis with radiologists of varying expertise levels is also conducted. The proposed model exhibited the highest performance, achieving an AUC of 0.9320 on our private dataset and an area under the curve (AUC) of 0.9834 on the public dataset, significantly outperforming traditional deep convolutional neural network models. It also exceeded the diagnostic performance of radiologists, showcasing its potential as a reliable tool for medical image classification. The model's success can be attributed to its incorporation of advanced architectures, feature fusion, and attention mechanisms. The model's decision-making process was further clarified using interpretability techniques like Grad-CAM, Saliency Maps, and SHAP, offering insights into its ability to focus on relevant image features for accurate classification. The proposed deep learning model offers superior accuracy in classifying benign and malignant lesions in ultrasound images, outperforming traditional models and radiologists. Its strong performance, coupled with interpretability techniques, demonstrates its potential as a reliable and efficient tool for medical diagnostics. The datasets generated and analyzed during the current study are not publicly available due to the nature of this research and participants of this study, but may be available from the corresponding author on reasonable request.

Valid non-invasive biomarkers for Parkinson's disease (PD) and Parkinson-plus syndrome (PPS) are urgently needed. Based on our recent self-supervised vision foundation model the Shift Window UNET TRansformer (Swin UNETR), which uses clinical multi-contrast whole brain MRI, we aimed to develop an efficient and practical model ('SwinClassifier') for the discrimination of PD vs PPS using routine clinical MRI scans. We used 75,861 clinical head MRI scans including T1-weighted, T2-weighted and fluid attenuated inversion recovery imaging as a pre-training dataset to develop a foundation model, using self-supervised learning with a cross-contrast context recovery task. Then clinical head MRI scans from n = 1992 participants with PD and n = 1989 participants with PPS were used as a downstream PD vs PPS classification dataset. We then assessed SwinClassifier's performance in confusion matrices compared to a comparative self-supervised vanilla Vision Transformer (ViT) autoencoder ('ViTClassifier'), and to two convolutional neural networks (DenseNet121 and ResNet50) trained from scratch. SwinClassifier showed very good performance (F1 score 0.83, 95% confidence interval [CI] [0.79-0.87], AUC 0.89) in PD vs PPS discrimination in independent test datasets (n = 173 participants with PD and n = 165 participants with PPS). This self-supervised classifier with pretrained weights outperformed the ViTClassifier and convolutional classifiers trained from scratch (F1 score 0.77-0.82, AUC 0.83-0.85). Occlusion sensitivity mapping in the correctly-classified cases (n = 160 PD and n = 114 PPS) highlighted the brain regions guiding discrimination mainly in sensorimotor and midline structures including cerebellum, brain stem, ventricle and basal ganglia. Our self-supervised digital model based on routine clinical head MRI discriminated PD vs PPS with good accuracy and sensitivity. With incremental improvements the approach may be diagnostically useful in early disease. National Key Research and Development Program of China.

The methods for predicting time-to-total knee replacement (TKR) do not provide enough information to make robust and accurate predictions. Develop and evaluate an artificial intelligence-based model for predicting time-to-TKR by analyzing longitudinal knee data and identifying key features associated with accelerated knee osteoarthritis progression. A total of 547 subjects underwent TKR in the Osteoarthritis Initiative over nine years, and their longitudinal data was used for model training and testing. 518 and 164 subjects from Multi-Center Osteoarthritis Study and internal hospital data were used for external testing, respectively. The clinical variables, magnetic resonance (MR) images, radiographs, and quantitative and semi-quantitative assessments from images were analyzed. Deep learning (DL) models were used to extract features from radiographs and MR images. DL features were combined with clinical and image assessment features for survival analysis. A Lasso Cox feature selection method combined with a random survival forest model was used to estimate time-to-TKR. Utilizing only clinical variables for time-to-TKR predictions provided the estimation accuracy of 60.4% and C-index of 62.9%. Combining DL features extracted from radiographs, MR images with clinical, quantitative, and semi-quantitative image assessment features achieved the highest accuracy of 73.2%, (p=.001) and C-index of 77.3% for predicting time-to-TKR. The proposed predictive model demonstrated the potential of DL models and multimodal data fusion in accurately predicting time-to-TKR surgery that may help assist physicians to personalize treatment strategies and improve patient outcomes.

Alzheimer's disease (AD) is a devastating neurological disorder that affects humans and is a major contributor to dementia. It is characterized by cognitive dysfunction, impairing an individual's ability to perform daily tasks. In AD, nerve cells in areas of the brain related to cognitive function are damaged. Despite extensive research, there is currently no specific therapeutic or diagnostic approach for this fatal disease. However, scientists worldwide have developed effective techniques for diagnosing and managing this challenging disorder. Among the various methods used to diagnose AD are feedback from blood relatives and observations of changes in an individual's behavioral and cognitive abilities. Biomarkers, such as amyloid beta and measures of neurodegeneration, aid in the early detection of Alzheimer's disease (AD) through cerebrospinal fluid (CSF) samples and brain imaging techniques like Magnetic Resonance Imaging (MRI). Advanced medical imaging technologies, including X-ray, CT, MRI, ultrasound, mammography, and PET, provide valuable insights into human anatomy and function. MRI, in particular, is non-invasive and useful for scanning both the structural and functional aspects of the brain. Additionally, Machine Learning (ML) and deep learning (DL) technologies, especially Convolutional Neural Networks (CNNs), have demonstrated high accuracy in diagnosing AD by detecting brain changes. However, these technologies are intended to support, rather than replace, clinical assessments by medical professionals.

Epilepsy is a multifaceted neurological disorder marked by seizures that can present with a wide range of symptoms. Despite the prevalent use of anti-epileptic drugs, drug resistance and adverse effects present considerable obstacles. Despite advancements in anti-epileptic drugs (AEDs), approximately 20-30% of patients remain drug-resistant, highlighting the need for innovative therapeutic strategies. This study aimed to explore advancements in epilepsy diagnosis and treatment utilizing modern technology and medicines. The literature survey was carried out using Scopus, ScienceDirect, and Google Scholar. Data from the last 10 years were preferred to include in the study. Emerging technologies, such as artificial intelligence, gene therapy, and wearable gadgets, have transformed epilepsy care. EEG and MRI play essential roles in diagnosis, while AI aids in evaluating big datasets for more accurate seizure identification. Machine learning and artificial intelligence are increasingly integrated into diagnostic processes to enhance seizure detection and classification. Wearable technology improves patient self-monitoring and helps clinical research. Furthermore, gene treatments offer promise by treating the fundamental causes of seizure activity, while stem cell therapies give neuroprotective and regenerative advantages. Dietary interventions, including ketogenic diets, are being examined for their ability to modify neurochemical pathways implicated in epilepsy. Recent technological and therapeutic developments provide major benefits in epilepsy assessment and treatment, with AI and wearable devices enhancing seizure detection and patient monitoring. Nonetheless, additional study is essential to ensure greater clinical application and efficacy. Future perspectives include the potential of optogenetics and advanced signal processing techniques to revolutionize treatment paradigms, emphasizing the importance of personalized medicine in epilepsy care. Overall, a comprehensive understanding of the multifaceted nature of epilepsy is essential for developing effective interventions and improving patient outcomes.

Suicide represents an egregious threat to society despite major advancements in medicine, in part due to limited knowledge of the biological mechanisms of suicidal behavior. We apply a connectome predictive modeling machine learning approach to identify a reproducible brain network associated with suicidal ideation in the hopes of demonstrating possible targets for novel anti-suicidal therapeutics. Patients were recruited from an inpatient facility at The Menninger Clinic, in Houston, Texas (N = 261; 181 with active and specific suicidal ideation) and had a current major depressive episode and recurrent major depressive disorder, underwent resting-state functional magnetic resonance imaging. The participants' ages ranged from 18 to 70 (mean ± SEM = 31.6 ± 0.8 years) and 136 (52 %) were males. Using this approach, we found a robust and reproducible biomarker of suicidal ideation relative to controls without ideation, showing that increased suicidal ideation was associated with greater internal connectivity and reduced internetwork external connectivity in the central executive, default mode, and dorsal salience networks. We also found evidence for higher external connectivity between ventral salience and sensorimotor/visual networks as being associated with increased suicidal ideation. Overall, these observed differences may reflect reduced network integration and higher segregation of connectivity in individuals with increased suicide risk. Our findings provide avenues for future work to test novel drugs targeting these identified neural alterations, for instance drugs that increase network integration.

This research aims to develop an advanced deep-learning framework for detecting respiratory diseases, including COVID-19, pneumonia, and tuberculosis (TB), using chest X-ray scans. A Deep Neural Network (DNN)-based system was developed to analyze medical images and extract key features from chest X-rays. The system leverages various DNN learning algorithms to study X-ray scan color, curve, and edge-based features. The Adam optimizer is employed to minimize error rates and enhance model training. A dataset of 1800 chest X-ray images, consisting of COVID-19, pneumonia, TB, and typical cases, was evaluated across multiple DNN models. The highest accuracy was achieved using the VGG19 model. The proposed system demonstrated an accuracy of 94.72%, with a sensitivity of 92.73%, a specificity of 96.68%, and an F1-score of 94.66%. The error rate was 5.28% when trained with 80% of the dataset and tested on 20%. The VGG19 model showed significant accuracy improvements of 32.69%, 36.65%, 42.16%, and 8.1% over AlexNet, GoogleNet, InceptionV3, and VGG16, respectively. The prediction time was also remarkably low, ranging between 3 and 5 seconds. The proposed deep learning model efficiently detects respiratory diseases, including COVID-19, pneumonia, and TB, within seconds. The method ensures high reliability and efficiency by optimizing feature extraction and maintaining system complexity, making it a valuable tool for clinicians in rapid disease diagnosis.

The fetal origins of adult disease, widely known as Barker's Hypothesis, suggest that adverse fetal environments significantly impact the risk of developing chronic diseases, such as diabetes and cardiovascular conditions, in adulthood. Recent advancements in 4D ultrasound (4D US) and artificial intelligence (AI) technologies offer a promising avenue for improving prenatal diagnostics and validating this hypothesis. These innovations provide detailed insights into fetal behavior and neurodevelopment, linking early developmental markers to long-term health outcomes. This study synthesizes contemporary developments in AI-enhanced 4D US, focusing on their roles in detecting fetal anomalies, assessing neurodevelopmental markers, and evaluating congenital heart defects. The integration of AI with 4D US allows for real-time, high-resolution visualization of fetal anatomy and behavior, surpassing the diagnostic precision of traditional methods. Despite these advancements, challenges such as algorithmic bias, data diversity, and real-world validation persist and require further exploration. Findings demonstrate that AI-driven 4D US improves diagnostic sensitivity and accuracy, enabling earlier detection of fetal abnormalities and optimization of clinical workflows. By providing a more comprehensive understanding of fetal programming, these technologies substantiate the links between early-life conditions and adult health outcomes, as proposed by Barker's Hypothesis. The integration of AI and 4D US has the potential to revolutionize prenatal care, paving the way for personalized maternal-fetal healthcare. Future research should focus on addressing current limitations, including ethical concerns and accessibility challenges, to promote equitable implementation. Such advancements could significantly reduce the global burden of chronic diseases and foster healthier generations.

A critical limitation to deployment and utilization of Artificial Intelligence (AI) algorithms in radiology practice is the actual integration of algorithms directly into the clinical Picture Archiving and Communications Systems (PACS). Here, we sought to integrate an AI-based pipeline for prostate organ and intraprostatic lesion segmentation within a clinical PACS environment to enable point-of-care utilization under a prospective clinical trial scenario. A previously trained, publicly available AI model for segmentation of intra-prostatic findings on multiparametric Magnetic Resonance Imaging (mpMRI) was converted into a containerized environment compatible with MONAI Deploy Express. An inference server and dedicated clinical PACS workflow were established within our institution for evaluation of real-time use of the AI algorithm. PACS-based deployment was prospectively evaluated in two phases: first, a consecutive cohort of patients undergoing diagnostic imaging at our institution and second, a consecutive cohort of patients undergoing biopsy based on mpMRI findings. The AI pipeline was executed from within the PACS environment by the radiologist. AI findings were imported into clinical biopsy planning software for target definition. Metrics analyzing deployment success, timing, and detection performance were recorded and summarized. In phase one, clinical PACS deployment was successfully executed in 57/58 cases and were obtained within one minute of activation (median 33 s [range 21-50 s]). Comparison with expert radiologist annotation demonstrated stable model performance compared to independent validation studies. In phase 2, 40/40 cases were successfully executed via PACS deployment and results were imported for biopsy targeting. Cancer detection rates for prostate cancer were 82.1% for ROI targets detected by both AI and radiologist, 47.8% in targets proposed by AI and accepted by radiologist, and 33.3% in targets identified by the radiologist alone. Integration of novel AI algorithms requiring multi-parametric input into clinical PACS environment is feasible and model outputs can be used for downstream clinical tasks.